Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $60.00 → $45.00 | Buy → Neutral | B. Riley Securities |
| 3/7/2022 | $145.00 → $70.00 | Buy | B. Riley Securities |
| 11/2/2021 | $175.00 → $145.00 | Buy | B. Riley Securities |
| 10/26/2021 | $151.00 → $175.00 | Buy | B. Riley Securities |
SANTA CLARA, Calif., April 30, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, its at-the-market equity offering (ATM) program and first quarter earnings release date and conference call. BTC Update Between April 25, 2025 and April 29, 2025, Semler Scientific acquired 165 bitcoins for $15.7 million with an average purchase price of $94,931 pe
SANTA CLARA, Calif., April 25, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, as well as its at-the-market equity offering (ATM) programs. BTC Update Between February 14, 2025 and April 24, 2025, Semler Scientific acquired 111 bitcoins for $10.0 million with an average purchase price of $90,124 per bitcoin, inclusive of fees and expenses, using p
SANTA CLARA, Calif., Feb. 18, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. "We are again pleased to report strong performance from our healthcare business with income from operations of $20.9 million for the full year 2024," said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. "While we continue to support innovation and growth
SANTA CLARA, Calif., July 11, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced the appointment of a chief financial officer (CFO), record quarterly revenues expected for the second quarter of 2023 and a strategic streamlining. "We are pleased to announce Ms. Renae Cormier will lead our accounting, finance, investor relations and business strategy efforts as chief financial officer," said Doug Murphy-Chuto
Eric Semler Appointed as Chairman SANTA CLARA, Calif., April 19, 2023 /PRNewswire/ -- - Semler Scientific, Inc. (NASDAQ:SMLR) today announced that Eric Semler and William H.C. Chang (together, the "Investors"), who collectively beneficially own more than 20% of Semler Scientific's outstanding shares, will immediately join Semler Scientific's board of directors as new independent directors. Mr. Semler will join the board as a Class II director standing for reelection at the 2023 annual meeting of stockholders and will be appointed as Chairman of the board, and Mr. Chang will join the board as a Class I director standing for reelection at the 2025 annual meeting of stockholders. The board will
SANTA CLARA, Calif., March 21, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, announces that Doug Murphy-Chutorian, M.D. has informed the board of directors of his intention to step down from his position as chief executive officer (CEO) of Semler Scientific and assist for a transition period. He will continue to serve as a member of the board of directors at least through the remainder of his 2024 term. "I am proud of the business that we hav
8-K - Semler Scientific, Inc. (0001554859) (Filer)
8-K - Semler Scientific, Inc. (0001554859) (Filer)
8-K - Semler Scientific, Inc. (0001554859) (Filer)
B. Riley Securities downgraded Semler Scientific from Buy to Neutral and set a new price target of $45.00 from $60.00 previously
B. Riley Securities reiterated coverage of Semler Scientific with a rating of Buy and set a new price target of $70.00 from $145.00 previously
B. Riley Securities reiterated coverage of Semler Scientific with a rating of Buy and set a new price target of $145.00 from $175.00 previously
4 - Semler Scientific, Inc. (0001554859) (Issuer)
SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)
SC 13G - Semler Scientific, Inc. (0001554859) (Subject)
SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)
SANTA CLARA, Calif., April 30, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, its at-the-market equity offering (ATM) program and first quarter earnings release date and conference call. BTC Update Between April 25, 2025 and April 29, 2025, Semler Scientific acquired 165 bitcoins for $15.7 million with an average purchase price of $94,931 pe
SANTA CLARA, Calif., April 25, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, as well as its at-the-market equity offering (ATM) programs. BTC Update Between February 14, 2025 and April 24, 2025, Semler Scientific acquired 111 bitcoins for $10.0 million with an average purchase price of $90,124 per bitcoin, inclusive of fees and expenses, using p
SANTA CLARA, Calif., Feb. 18, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. "We are again pleased to report strong performance from our healthcare business with income from operations of $20.9 million for the full year 2024," said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. "While we continue to support innovation and growth
4 - Semler Scientific, Inc. (0001554859) (Issuer)
4 - Semler Scientific, Inc. (0001554859) (Issuer)
4 - Semler Scientific, Inc. (0001554859) (Issuer)